Amylyx Pharmaceuticals Inc
United States of America
Dr. Milne began serving as a director of Amylyx in 2015. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. Milne has served on the Board of Directors at many different companies and organizations including currently Charles River Laboratories, Mettler-Toledo, Inc., BioStorage Technologies Inc., Draper Laboratory, the Sea Research Foundation and the New York Botanical Garden. During his notable career, Milne has received a variety of honors, including an award from Yale University for lifetime contributions to commerce, innovation or education, the Connecticut College medal and the distinguished citizen award from Big Brothers/Big Sisters. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.
mylyx is developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary combination of existing compounds that Amylyx has demonstrated have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models.